Geode Capital Management LLC Has $227.04 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Geode Capital Management LLC increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,233,211 shares of the medical research company's stock after purchasing an additional 14,787 shares during the quarter. Geode Capital Management LLC owned approximately 2.41% of Charles River Laboratories International worth $227,042,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of CRL. National Bank of Canada FI increased its stake in Charles River Laboratories International by 12.4% in the 4th quarter. National Bank of Canada FI now owns 23,855 shares of the medical research company's stock valued at $4,396,000 after buying an additional 2,639 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after buying an additional 335,658 shares during the last quarter. Mawer Investment Management Ltd. grew its stake in shares of Charles River Laboratories International by 14.1% in the 4th quarter. Mawer Investment Management Ltd. now owns 46,629 shares of the medical research company's stock valued at $8,608,000 after buying an additional 5,769 shares in the last quarter. Allstate Corp acquired a new position in Charles River Laboratories International in the fourth quarter worth approximately $277,000. Finally, Brown Brothers Harriman & Co. raised its holdings in shares of Charles River Laboratories International by 190.3% during the 4th quarter. Brown Brothers Harriman & Co. now owns 389 shares of the medical research company's stock valued at $72,000 after purchasing an additional 255 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In other news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded down $13.56 during trading on Thursday, reaching $125.52. The company's stock had a trading volume of 672,448 shares, compared to its average volume of 1,198,487. The stock has a 50-day moving average price of $159.23 and a two-hundred day moving average price of $178.36. The stock has a market capitalization of $6.16 billion, a P/E ratio of 837.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a one year low of $117.26 and a one year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 earnings per share. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on CRL shares. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. cut their price target on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Bank of America decreased their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. UBS Group restated a "neutral" rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, Mizuho lowered their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).